Protocol Writing
& CRF Design

The manner in which a protocol is put together is equally important to the data produced and how it is presented, as it dictates the way a study will be conducted.

Richmond Pharmacology’s Medical Writing Department has considerable experience in producing Clinical Study Protocols and Study Reports according to ICH guidelines. Each protocol is developed in collaboration with the Sponsor in order to fulfil Sponsor requirements and objectives. All protocols are written by Richmond Pharmacology’s medical writing team, with input from Richmond Pharmacology’s Medical Director.

Our dedicated CRF design team use Indesign to create Case Report Forms, Source documentation, Diaries and Urinalysis booklets. Each CRF is based on our RPL standard library of CRF modules (in accordance with CDISC). However Richmond Pharmacology will modify or create CRFs in accordance with your needs to ensure you receive the module you specifically require.

CRF instructions are prepared alongside the design of the CRF to ensure site staff are very clear on how to complete the required pages. These can be incorporated into the document itself or can be a standalone document.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more